SEARCH BY NAME

BROWSE

Browse Australian delisted companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse terminated Australian managed funds

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

AIRXPANDERS, INC. (AXP)

Delisted from ASX 28/08/2019

SHARE PRICES

(discontinued 17 July 2020)

Former (or subsequent) names

 

Shareholder links

Our website ranking of AXP: rating 4
(4 out of 5)

 

Company details

Address: c/- Case Corporate Governance Pty Ltd, Level 13, 41 Exhibition Street, MELBOURNE, VIC, AUSTRALIA, 3000
Tel:  0011 1 650 390 9000 Fax: 0011 1 650 390 9007

Date first listed: 22/06/2015
Company Secretary: Brendan Case
Sector: Health Care Equipment & Services INC.
Industry Group: 
Activities: 

the local registered entity of this company is deregistered today

03/03/2020

delisted from the close of trading on Wednesday, 28 August 2019 pursuant to Listing rule 17.15.

28/08/2019

we understand this company failed to pay its annual listing fee on due date and ASX has accordingly removed it from the official list

28/08/2019

The company has not paid their annual listing fees in respect of the year ending 30 June 2020 but the securities are already suspended from official quotation.

22/08/2019

The company has filed a voluntary petition for the relief under the provisions of Chapter 7 of Title 11 of the United States Code in the United States Bankruptcy Court for the Northern District of California on July 24, 2019. As a result of this filing, a Chapter 7 trustee will be appointed by the Bankruptcy Court and will assume control of the company. The assets of the company will be liquidated and paid in accordance with the code.

25/07/2019

The company has reduced its workforce and plans to cease operations. The company plans to immediately reduce its number of employees from approximately 35 to approximately 8, with further reductions planned for the near future. The company is also ceasing the sale of all products immediately, and will not be providing customer service or sales support after 18 July 2019. The company anticipates filing a petition for relief under chapter 7 of Title 11 of the United States Code no later than 26 July 2019.

17/07/2019

The company has received U.S. FDA 510(k) clearance to market a smooth shell version of the AeroForm Tissue Expander.

16/07/2019

The company has received a notice of proposal to suspend the AeroForm Patent Controlled Tissue Expander from the Australian Register of Therapeutic Goods. Suspension of AeroForm from the Register would result in the cessation of sales and distribution of AeroForm in Australia for a period of six months. The Australian Therapeutic Goods Administration has notified Emergo Australia, AirXpanders' sponsor in the Australian market, of this notice.

10/07/2019

The company announces prelimininary second quarter total revenue of $1.87 million. U.S. revenue was approximately $1.79 mm, up 14% from Q1 2019.

09/07/2019

The company is extending the voluntary suspension of trading until it can finalise its review of the financial and strategic alternatives, and provide the market with an accurate update on its future plans. The company expects plans to be finalised and an announcement to be made on 31 July 2019.

26/06/2019

The company has entered into a forbearance agreement with respect to the company's loan and security agreement dated 4 August 2017, as amended, with Oxford Finance. The effective date is expected to be 19 June 2019, when the company will transfer US$500,000 to a restricted account under the sole control of Oxford Finance. Under the agreement, Oxford has agreed that it will forbear, during the foreberance period, from filing any legal action or instituting or enforcing any rights and remedies it may have against the company in connection with existing and ongoing defaults under the agreement.

19/06/2019

The company is extending the voluntary suspension of trading until it can finalise its review of financial and strategic alternatives, and provide the market with an accurate update on its future plans. The voluntary suspension is expected to continue until an announcement is made regarding the aforementioned or by 1 July 2019. The 2019 Annual Meeting of Stockholders previously scheduled on Thursday, 20 June 2019 at 9.00am Australian Eastern Standard Time (Wednesday, 19 June 2019 at 4.00pm U.S. Pacific Daylight Time) has been postponed due to the potential need for additional shareholder approvals to support the financial and strategic alternatives being considered.

17/05/2019

The company lodges its 31 March 2019 Form 10Q.

16/05/2019

The company lodges its 31 March 2019 Form 10Q.

16/05/2019

In light of the recently announced organizational restructure, the Company no longer expects to achieve net revenues for 2019 of between US$11.5 million and US$14 million. The Company is not able to provide revised revenue guidance at this stage as it works through its current restructuring and explores financial and strategic alternatives. The Company also expects that it will breach its minimum net revenue covenant for the month of April under its debt facility with Oxford Finance, LLC.

13/05/2019

The company has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alternatives. With Cowen's assistance, the Company will continue to evaluate opportunities to explore a wide range of financial and strategic alternatives, including a capital raise, that could enhance stockholder value and enable the Company to continue serving other important constituencies, including patients and physicians.

09/05/2019

The company is extendinbg the voluntary suspension of trading until it can finalize its negotiations and provide the market with an accurate update on its future plans. The voluntary suspension is expected to continue until plans are finalised and an announcement is made or by 20 May 2019.

03/05/2019

The company has initiated an organizational restructuring to better align and focus the company while making best use of its resources. The company expects the restructuring to include an organizational resizin, representing a reduction of approximately 45% of the workforce, resulting in an expected reduction in quarterly use of cash of approximately 33% on an ongoing basis. The company anticipates it will incur aggregate one-time restructuring charges of approximately US$0.2 million in the second quarter of 2019. This restructuring is intended to reduce use of cash, while ensuring continued progress in driving adoption of the AeroForm Tissue Expander System. The company is actively pursuing capital raising opportunities, and recently filed a preliminary S-1 outlining the potential terms of an offering with the SEC.

02/05/2019

The company lodges an Appendix 4C.

30/04/2019

The company releases its 2018 Appendix 4G.

26/04/2019

The company releases its 2018 Corporate Governance Statement.

26/04/2019

The company lodges its Annual Report 2018.

26/04/2019

The company changed the date of its 2019 AGM to Thursday, 20 June 2019 at 9.00am Australian Eastern Standard Time (Wednesday, 19 June 2019 at 4.00pm U.S. Pacific Daylight Time). The 2019 Annual Meeting will be held at the Melbourne office of Johnson Winter & Slattery, Level 34, 55 Collins Street, Melbourne, Victoria, Australia.

24/04/2019

The company filed a Form S-1 Registration Statement with the U.S. SEC. The Form S-1 relates to a proposed rights offering and is an interim filing only. The company intends that the current voluntary suspension of trading of its securities remain in place at least 6 May 2019.

23/04/2019

AirXpanders and Radformation have entered into a co-marketing agreement to introduce Radformation's EZFluence software to Radiation Oncology departments that are treating AeroForm patients in the U.S.

09/04/2019

The company announces new data demonstrating reduced infection rates and decreased utilisation of healthcare resources associated with AeroForm.

04/04/2019

The company voluntarily suspends its securities while the company reviews and finalises various matters pertaining to its operations, including resolving an anticipated debt covenant breach with its lender and while the company continues to evaluate opportunities to raise additional capital, including related terms and timing.

02/04/2019

The securities of AirXpanders Inc. will be suspended from quotation immediately under Listing Rule 17.2, at the request of AXP, pending the release of an announcement regarding a negotiation with its lender and an assessment of capital raising options.

02/04/2019

The securities of AirXpanders, Inc will be reinstated to quotation from the commencement of trading on Friday, 27 January 2017 following the release of an announcement by the Company.

27/01/2017

The company lodges its Appendix 4C "“ Quarterly Cash Flow Report and Business Update.

27/01/2017

Commitments were received under private placement from sophisticated and professional investors to raise A$45 million at an issue price of A$0.92 per CDI. Proceeds will be used primarily to build inventory for the U.S. market, accelerate investment for U.S. sales and marketing, complete commercial manufacturing capacity expansion and for general working capital.

27/01/2017

The securities of AirXpanders, Inc. will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company.

25/01/2017

listed entity carried for record purposes only

22/06/2015

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    loading Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNATURENUMBERPRICEAMOUNT
    08/05/2018Zita Peach83,333$0.130$10,833

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Barry CheskinChairman22/06/201524/07/2019
    Frank GrilloPresident, CEO12/06/201824/07/2019
    Gregory LichtwardtNon Exec Director17/05/201624/07/2019
    Elizabeth HammackNon Exec Director23/05/201724/07/2019
    Dennis CondonDirector22/06/201524/07/2019
    Zita PeachDirector15/07/2019
    Scott MurcrayCFO, COO06/06/201607/06/2019
    Scott DodsonExecutive Director, CEO22/06/201509/04/2018
    Teddy ShalonDirector22/06/201523/05/2017
    Brigitte SmithManaging Director22/06/201517/05/2016
    Albert ChaManaging Director22/06/201517/05/2016

    Date of first appointment, title may have changed.